John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into…
The Biosecure Act has been excluded from a recent key defense spending bill, leaving its future unclear. But whether or not it ends up being passed, the legislation has already…
A summary of some of the biggest stories coming out of Japan’s pharma industry, including Teva’s divestment of joint venture Teva-Takeda; GE HealthCare’s takeover of Nihon Medi-Physics; Takeda’s blood cancer…
The World Health Organisation has highlighted antimicrobial resistance (AMR) as one of the leading global public health and development threats today. AMR occurs when bacteria, viruses, fungi and parasites change…
Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of…
Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational…
Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer,…
Switzerland is a highly decentralised nation where much of the decision-making power lies within individual Cantons and where the Federal presidency is rotated annually. To consistently keep industry interests on…
Switzerland’s healthcare system is globally renowned. It leads the world on metrics such as infrastructure, medical advances, and patient freedom to choose healthcare services, and ranks 1st in US thinktank…
Switzerland has a vital role to play in global health, especially in the world’s poorest countries. Indisputably the global capital for health and humanitarian work, its political neutrality, central European…
As home to much of Europe’s innovative medicine output and as one of its wealthiest nations per capita, Switzerland has not traditionally been a generic-friendly market. Generics prices are relatively…
Although the global biotech sector is currently struggling with equity and debt financing, Swiss biotech is on the up. 2023 saw the Swiss biotech sector hit record revenues of CHF…
See our Cookie Privacy Policy Here
